ClinicalTrials.gg
CompletedNCT06793943Updated Apr 4, 2025

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

A Phase 1 interventional study of Zasocitinib and COC in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Takeda · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main aim of this study is to find out how zasocitinib (TAK-279) interacts with other medicines taken by mouth (orally). This will be examined by how the body processes medicines, which is called pharmacokinetics or PK. In this study, other medicines that will be administered together with zasocitinib include a contraceptive (levonorgestrel (LNG) and ethinyl estradiol [EE]), a medicine for diabetes (metformin), a medicine used for heart problems (digoxin), and a medicine that blocks the production of stomach acid (esomeprazole).

Another aim is to learn about the side effects of zasocitinib and how well it is tolerated when taken alone and together with these other medicines.

During the study, participants will need to stay at the clinic for up to 27 days.

Read the detailed description

The drug being tested in this study is called zasocitinib.

Zasocitinib is being tested to assess the effect of zasocitinib on the pharmacokinetics of Combined Oral Contraceptive (COC [containing LNG and EE] in Part 1), multidrug and toxic compound extrusion (MATE) substrate (metformin in Part 2), and a P-glycoprotein (P-gp) substrate (digoxin in Part 3). Additionally, the effect of proton-pump inhibitor (PPI) (esomeprazole in Part 4) on the pharmacokinetics of zasocitinib is being evaluated in healthy participants.

The study will enroll approximately 78 participants. Participants will be enrolled in one of the four parts to evaluate the following treatments:

  • Part 1: COC (LNG and EE) + Zasocitinib
  • Part 2: Metformin + Zasocitinib
  • Part 3: Digoxin + Zasocitinib
  • Part 4: Zasocitinib + Esomeprazole

The overall time (including screening and follow-up periods) to participate is approximately 68 days for Part 1, 54 days for Part 2, 62 days for Part 3 and 56 days for Part 4. All participants will be followed up for up to 14 days after the last dose of Period 2 in each Part.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) greater than or equal to (>=) 18.0 and less than or equal to (\<=) 32.0 kilograms per square meter (kg/m\^2) at the screening visit.
  2. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs, and (ECGs) as outlined in the protocol.

    Part 1 Only:

  3. Healthy, adult, female, aged 18 to 65 years, inclusive, at the screening visit.

    Parts 2-4 Only:

  4. Healthy, adult, male or female, aged 18 to 55 years, inclusive, at the screening visit.

Exclusion criteria

Exclusion criteria:

  1. Positive urine drug or alcohol results at the screening visit or at check-in.
  2. Unable to refrain from or anticipates the use of:

    • Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements and other drugs outlined in protocol.
    • Any drugs known to be inducers of Cytochrome P450 3A4 () and/or P-gp, including St. John's Wort, for 28 days prior to the first dosing.
  3. Has been on a diet incompatible with the on-trial diet, in the opinion of the investigator or designee, within the 30 days prior to first dosing and throughout the trial.
  4. Has made a donation of blood or had significant blood loss within 56 days prior to first dosing.
  5. Has made a plasma donation within 7 days prior to first dosing.
  6. Participated in another clinical trial within 30 days prior to first dosing. The 30-day window will be derived from the date of the last dosing in the previous trial to Day 1 of Period 1 of the current trial.
  7. Has herpes infections.
  8. Positive results for non-herpetic viral diseases at the screening visit.
  9. Positive results for tuberculosis (TB) at the screening visit.

    Part 1:

  10. Unable to refrain from or anticipates the use of:

    • Any drugs known to increase or decrease levels of sex hormone-binding globulin (SHBG), including any oral, topical, or intravaginal hormone-containing product, within 12 weeks prior to the first dosing.
    • Any injectable or implantable hormone-containing product within 1 year prior to the first dosing.

    Part 2 Only:

  11. (HbA1c) greater than (>) (5.7 percentage [%]) and deemed by the investigator or designee at the screening visit.

    Part 3 Only:

  12. Has or is at risk for major cardiac events or dysfunction.

    Part 4 Only:

  13. Had diarrhea or vomiting within 48 hours prior to check-in.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Part 1: COC (LNG and EE) + Zasocitinib

    Drug: Zasocitinib · Drug: COC

  • Experimental
    Part 2: Metformin + Zasocitinib

    Drug: Zasocitinib · Drug: Metformin

  • Experimental
    Part 3: Digoxin + Zasocitinib

    Drug: Zasocitinib · Drug: Digoxin

  • Experimental
    Part 4: Zasocitinib + Esomeprazole

    Drug: Zasocitinib · Drug: Esomeprazole

Interventions

  • Zasocitinib tablets specified doses on specified days.

    Also known as: TAK- 279

  • DrugCOC

    COC tablets (containing LNG and EE) specified doses on specified days.

  • DrugMetformin

    Metformin tablets specified doses on specified days.

  • DrugDigoxin

    Digoxin tablets specified doses on specified days.

  • DrugEsomeprazole

    Esomeprazole capsules specified doses on specified days.

06

What researchers measure

Primary outcomes

  1. Part 1: Cmax: Maximum Observed Plasma Concentration for LNG and EE When Administered Alone and With Zasocitinib

    Time frame: Up to 144 hours

  2. Part 1: AUCinf: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for LNG and EE When Administered Alone and With Zasocitinib

    Time frame: Up to 144 hours

  3. Part 1: AUClast: Area Under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration for LNG and EE When Administered Alone and With Zasocitinib

    Time frame: Up to 144 hours

  4. Part 2: Cmax for Metformin When Administered Alone and With Zasocitinib

    Time frame: Up to 48 hours

  5. Part 2: AUCinf for Metformin When Administered Alone and With Zasocitinib

    Time frame: Up to 48 hours

  6. Part 2: AUClast for Metformin When Administered Alone and With Zasocitinib

    Time frame: Up to 48 hours

  7. Part 3: Cmax for Digoxin When Administered Alone and With Zasocitinib

    Time frame: Up to 144 hours

  8. Part 3: AUCinf for Digoxin When Administered Alone and With Zasocitinib

    Time frame: Up to 144 hours

  9. Part 3: AUClast for Digoxin When Administered Alone and With Zasocitinib

    Time frame: Up to 144 hours

  10. Part 4: Cmax for Zasocitinib When Administered Alone and With Esomeprazole

    Time frame: Up to 120 hours

  11. Part 4: AUCinf for Zasocitinib When Administered Alone and With Esomeprazole

    Time frame: Up to 120 hours

  12. Part 4: AUClast for Zasocitinib When Administered Alone and With Esomeprazole

    Time frame: Up to 120 hours

Secondary outcomes

  1. Parts 1, 2, 3 and 4: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)

    Time frame: Part 1: Up to 33 days; Part 2: Up to 23 days; Part 3: Up to 27 days; Part 4: Up to 23 days

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Mar 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2025
First posted
Jan 27, 2025
StartActual
Jan 23, 2025
Primary completionActual
Mar 11, 2025
CompletionActual
Mar 30, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06793943
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Jan 23, 2025
Primary completion
Mar 11, 2025
Completion
Mar 30, 2025
Last update
Apr 4, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zasocitinib

Start the discussion